Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
NEW YORK (Reuters Health) – Long-term results confirm that use of neoadjuvant chemotherapy in treating muscle-invasive cancer of the bladder confers a significant survival advantage, an international collaborative…
NEW YORK (Reuters Health) – Contrary to previous findings, patients with advanced cancer do not have significantly improved survival when they are treated with a low-molecular-weight heparin, European…
NEW YORK (Reuters Health) – The combination of etanercept and cyclophosphamide might be a risky one in patients with Wegener’s Granulomatosis, especially with those who have long-term, chronic…
NEW YORK (Reuters Health) – In most patients with localized renal cancer, simple enucleation may provide results equivalent to those of standard partial nephrectomy, Italian researchers report in…
NEW YORK (Reuters Health) – For patients with advanced, untreated non-small-cell lung cancer, the American Society of Clinical Oncology recommends that the tumor be tested for genetic mutations…
NEW YORK (Reuters Health) – The risk of pancreatic malignancy is increased in patients with diabetes, researchers from Taiwan report in a pre-print version of a study that…
NEW YORK (Reuters Health) – In women with metastatic breast cancer, a longer duration of chemotherapy is associated with a clinically meaningful and statistically significant improvement in time…
NEW YORK (Reuters Health) – Fifteen years after postoperative pelvic radiotherapy for endometrial carcinoma, many women still suffer from urinary and bowel symptoms and have reduced physical functioning,…
NEW YORK (Reuters Health) – A pH-balanced vaginal gel can alleviate vulvovaginal symptoms after treatment for breast cancer, according to results of randomized controlled study published in the…
NEW YORK (Reuters Health) – When the infusion time of high-dose methotrexate (HDMTX) is shortened from 24 hours to 4 hours in cases of childhood acute lymphoblastic leukemia…
